EA014527B1 - Вакцины против хламидиоза - Google Patents

Вакцины против хламидиоза Download PDF

Info

Publication number
EA014527B1
EA014527B1 EA200701825A EA200701825A EA014527B1 EA 014527 B1 EA014527 B1 EA 014527B1 EA 200701825 A EA200701825 A EA 200701825A EA 200701825 A EA200701825 A EA 200701825A EA 014527 B1 EA014527 B1 EA 014527B1
Authority
EA
Eurasian Patent Office
Prior art keywords
serovar
polypeptide
sch
motr
protein
Prior art date
Application number
EA200701825A
Other languages
English (en)
Russian (ru)
Other versions
EA200701825A1 (ru
Inventor
Бренда Барт
Аджай Бхатия
Марк Олдерсон
Жан-Франсуа Л. Мезоннёв
Ив Лобе
Флоренс Бернадетт Нозе
Мартин Маршан
Паскаль Меттен
Ясир А. Скейки
Питер Пробст
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Корикса Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А., Корикса Корпорейшн filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200701825A1 publication Critical patent/EA200701825A1/ru
Publication of EA014527B1 publication Critical patent/EA014527B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200701825A 2005-03-31 2006-03-24 Вакцины против хламидиоза EA014527B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66733105P 2005-03-31 2005-03-31
PCT/US2006/010793 WO2006104890A2 (en) 2005-03-31 2006-03-24 Vaccines against chlamydial infection

Publications (2)

Publication Number Publication Date
EA200701825A1 EA200701825A1 (ru) 2008-04-28
EA014527B1 true EA014527B1 (ru) 2010-12-30

Family

ID=36646973

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201001322A EA201001322A1 (ru) 2005-03-31 2006-03-24 Вакцины против хламидиоза
EA200701825A EA014527B1 (ru) 2005-03-31 2006-03-24 Вакцины против хламидиоза

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201001322A EA201001322A1 (ru) 2005-03-31 2006-03-24 Вакцины против хламидиоза

Country Status (16)

Country Link
US (1) US20090022755A1 (OSRAM)
EP (5) EP2392348A3 (OSRAM)
JP (2) JP2008534594A (OSRAM)
KR (1) KR20070121814A (OSRAM)
CN (2) CN103372206A (OSRAM)
AU (1) AU2006229968A1 (OSRAM)
BR (1) BRPI0609547A2 (OSRAM)
CA (1) CA2602637A1 (OSRAM)
EA (2) EA201001322A1 (OSRAM)
IL (1) IL186264A0 (OSRAM)
MA (1) MA30250B1 (OSRAM)
MX (1) MX2007012108A (OSRAM)
NO (1) NO20075069L (OSRAM)
SG (1) SG158145A1 (OSRAM)
UA (1) UA97943C2 (OSRAM)
WO (1) WO2006104890A2 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1891096A2 (en) 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
CL2008000611A1 (es) 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
WO2008156729A2 (en) * 2007-06-14 2008-12-24 Emergent Product Development Gaithersburg Inc. Vaccines against chlamydia infection
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
DK2907523T3 (en) * 2009-01-29 2018-07-16 British Columbia Cancer Agency Branch COMPOSITIONS COMPREHENSIVE KLAMYDIA ANTIGENES.
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
ES2788728T3 (es) 2010-05-28 2020-10-22 Spixia Biotechnology Ab Antígeno de la MOMP quimérica, método y uso
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
KR101275263B1 (ko) * 2011-04-01 2013-06-14 서울대학교산학협력단 조류 병원성 대장균 특이 박테리오파지 및 이를 포함하는 항균 조성물
EP2586789A1 (en) * 2011-08-11 2013-05-01 InGen Biosciences Method for diagnosing gram-negative infections
US8785145B2 (en) 2011-08-11 2014-07-22 Ingen Biosciences Method for diagnosing gram-negative infections
WO2013044398A1 (en) * 2011-09-30 2013-04-04 The University Of British Columbia Chlamydia antigen compositions and uses thereof
US9827319B2 (en) 2012-05-29 2017-11-28 The Research Foundation For The State University Of New York Combined therapy and prophylaxis for genital tract infections
CN104812406A (zh) * 2012-08-08 2015-07-29 英属哥伦比亚大学 衣原体抗原组合物及其用途
WO2015106345A1 (en) 2014-01-16 2015-07-23 Mcmaster University Type iii secretion injectisome proteins for treatment and prevention of chlamydial infections
WO2016081327A2 (en) * 2014-11-21 2016-05-26 Merck Sharp & Dohme Corp. Recombinant expression of chlamydia momp antigen
US10688171B2 (en) 2015-02-10 2020-06-23 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
EP3373961A4 (en) 2015-11-10 2019-07-31 Ohio State Innovation Foundation METHODS AND COMPOSITIONS ASSOCIATED WITH ACCELERATED HUMORAL AFFINITY
RU2676768C2 (ru) * 2016-05-12 2019-01-11 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Противохламидийная вакцина и способ ее получения
JP2020513836A (ja) * 2017-03-23 2020-05-21 オハイオ・ステイト・イノベーション・ファウンデーション 組換えクラミジア活性化ｂ細胞プラットフォーム及びその使用方法
CN108623657B (zh) * 2018-05-11 2021-02-12 苏州大学 多肽、重组dna分子、重组载体、外泌体及其应用
WO2022162177A1 (en) * 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2025076039A1 (en) * 2023-10-03 2025-04-10 The University Of North Carolina At Chapel Hill Chlamydial protease-like activity factor and adjuvant compositions and uses thereof
WO2025076210A1 (en) * 2023-10-03 2025-04-10 Vaxcyte, Inc. Chlamydia vaccine compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031236A1 (en) * 1995-04-03 1996-10-10 Smithkline Beecham Biologicals S.A. Chlamydia vaccines
WO1998028005A1 (en) * 1996-12-24 1998-07-02 Smithkline Beecham Biologicals S.A. Chlamydia vaccines
WO2002028998A2 (en) * 2000-10-02 2002-04-11 Antex Biologics, Inc. Chlamydia pmp proteins, gene sequences and uses thereof
WO2002062380A2 (en) * 2001-02-08 2002-08-15 Glaxosmithkline Biologicals S.A. Chlamydia vaccine composition
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
FI903345A7 (fi) 1988-01-04 1990-07-03 Du Pont Monivaiheinen affiniteettimenetelmä spesifisten solujen eristämiseksi soluseoksesta
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ES2103009T3 (es) 1990-10-18 1997-08-16 Cellpro Inc Un aparato y metodo para separar particulas utilizando un recipiente plegable.
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU666326B2 (en) 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1996038591A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
KR100769104B1 (ko) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2319309C (en) 1998-02-05 2010-08-10 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
IL143531A0 (en) * 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6166177A (en) 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
WO2002079244A2 (en) * 2001-03-30 2002-10-10 University Of Manitoba Chlamydial protease-like activity factor responsible for degradation of host transcription factor
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US6770753B2 (en) * 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
CN100515494C (zh) * 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
JP4896715B2 (ja) * 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031236A1 (en) * 1995-04-03 1996-10-10 Smithkline Beecham Biologicals S.A. Chlamydia vaccines
WO1998028005A1 (en) * 1996-12-24 1998-07-02 Smithkline Beecham Biologicals S.A. Chlamydia vaccines
US6555115B1 (en) * 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
WO2002028998A2 (en) * 2000-10-02 2002-04-11 Antex Biologics, Inc. Chlamydia pmp proteins, gene sequences and uses thereof
WO2002062380A2 (en) * 2001-02-08 2002-08-15 Glaxosmithkline Biologicals S.A. Chlamydia vaccine composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUNHAM R.C. et al., Immunolodgy of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.Nat. Rev. Immunol. 2005, 5 (2): 149-61 *
LU H. et al., GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vassination with inactivated Chlamydia trachomatis. J. Immunol. 2002, Dec. 1; 169 (11): 6324-31 *

Also Published As

Publication number Publication date
EP2392347A2 (en) 2011-12-07
UA97943C2 (ru) 2012-04-10
EP2392349A3 (en) 2012-01-18
MA30250B1 (fr) 2009-03-02
AU2006229968A1 (en) 2006-10-05
SG158145A1 (en) 2010-01-29
CA2602637A1 (en) 2006-10-05
IL186264A0 (en) 2008-01-20
MX2007012108A (es) 2007-12-05
EP2392348A2 (en) 2011-12-07
EP2392348A3 (en) 2012-01-18
EA200701825A1 (ru) 2008-04-28
CN101184504A (zh) 2008-05-21
EP2392349A2 (en) 2011-12-07
JP2008534594A (ja) 2008-08-28
JP2012180367A (ja) 2012-09-20
WO2006104890A2 (en) 2006-10-05
EA201001322A1 (ru) 2011-02-28
WO2006104890A3 (en) 2007-03-29
NO20075069L (no) 2007-12-27
EP2392347A3 (en) 2012-01-18
US20090022755A1 (en) 2009-01-22
EP1868641A2 (en) 2007-12-26
EP2386314A1 (en) 2011-11-16
BRPI0609547A2 (pt) 2011-10-18
KR20070121814A (ko) 2007-12-27
CN103372206A (zh) 2013-10-30

Similar Documents

Publication Publication Date Title
EA014527B1 (ru) Вакцины против хламидиоза
US7691993B2 (en) Fusion proteins of Mycobacterium tuberculosis
DE60130468T2 (de) Zusammensetzungen und verfahren zur behandlung von chlamydia-infektionen
US7261897B2 (en) Fusion proteins of mycobacterium tuberculosis
EP1278855B1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
EA012576B1 (ru) Новый способ предупреждения или лечения инфекции, вызываемой m.tuberculosis
ES2333579T3 (es) Proteinas de fusion de mycobacterium tuberculosis.
EA022203B1 (ru) Способы и композиции для лечения или предупреждения туберкулёза
WO2023064907A1 (en) Compositions and methods for vaccination against pathogenic coronavirus species and variants
HUP0302824A2 (hu) Vakcinakészítmények
JP2010505795A (ja) クラミジア感染症に対するワクチン
US20240026317A1 (en) PAN-RAS mRNA CANCER VACCINES
KR20230057403A (ko) 사람 시토메갈로바이러스 백신
CN101455846A (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
WO2021188818A1 (en) Vaccine constructs and compositions and methods of use thereof
TW202502375A (zh) 用於治療披衣菌之組合物
US8465748B2 (en) Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
US20140056967A1 (en) Vaccines against chlamydial infection
US20110300206A1 (en) Vaccines against chlamydial infection
US20230338511A1 (en) Single-chain coronavirus viral membrane protein complexes
WO2003020108A2 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
KR20010033132A (ko) 미코박테리움 바카이에서 유도한 조성물 및 이의 이용방법
HK1158961A (en) Vaccines against chlamydial infection
HK1158962A (en) Vaccines against chlamydial infection
HK1158963A (en) Vaccines against chlamydial infection

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU